Trials / Not Yet Recruiting
Not Yet RecruitingNCT04966416
Calcinosis Reduction by Pyrophosphate in SSC
The Effect of Orally Administered Pyrophosphate on Calcinosis Formation in Systematic Sclerosis
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Szeged University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test if orally administered pyrophosphate prevents calcinosis formation.
Detailed description
Calcinosis, the formation of hydroxyapatite subcutaneous nodules, often complicates systemic sclerosis. There is no standard treatment for it. Based upon our preclinical experienc, we would like to test it orally administered pyrophosphate inhibits calciosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Pyrophosphate | 50 mg/kg bwt once daily in gelatine capsules. |
| DIETARY_SUPPLEMENT | Placebo | Glucose in gelatine capsules. |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
- First posted
- 2021-07-19
- Last updated
- 2023-05-25
Source: ClinicalTrials.gov record NCT04966416. Inclusion in this directory is not an endorsement.